Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
16 hedge funds and large institutions have $29.2M invested in Taro Pharmaceutical Industries Ltd. in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 82 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
83% less funds holding
Funds holding: 94 → 16 (-78)
85% less capital invested
Capital invested by funds: $200M → $29.2M (-$171M)
93% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 82
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$128K |
| 2 |
KAM
Krensavage Asset Management
New York
|
+$94.3K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$8.45K |
| 4 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$5.05K |
| 5 |
MPWT
MassMutual Private Wealth & Trust
Windsor,
Connecticut
|
+$3.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$26.1M |
| 2 |
Renaissance Technologies
New York
|
-$24.2M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$22M |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$12M |
| 5 |
EP
Eversept Partners
New York
|
-$11.2M |
TARO Hedge Fund Activity: Q2 2024 in Review
16 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q2 2024, worth a combined $29.2M — down 85% from $200M a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of TARO and 6 opened new positions — a net loss of 76 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was RhumbLine Advisers, adding an estimated $128K. The largest seller was BlackRock, exiting entirely with an estimated $26.1M sold.
- 16 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q2 2024, down from 94 in Q1 2024.
- Funds reported $29.2M of Taro Pharmaceutical Industries Ltd. stock for Q2 2024, down 85% quarter-over-quarter.
- 6 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q2 2024 and 82 closed out, a net change of -76 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q2 2024 was RhumbLine Advisers, an estimated $128K added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q2 2024 was BlackRock, an estimated $26.1M sold.
Based on aggregated 13F filings for Q2 2024.